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Abstract: The interleukin-2 receptor antagonist basiliximab has proven in large clinical trials 
to be safe and effective to reduce acute rejections in the ﬁ  rst year after renal transplantation. 
Since acute rejections are a risk factor for chronic graft loss, their effective reduction might 
have a positive effect on long term allograft survival. So far data is spares to prove this hypoth-
esis and 10-year follow up on basiliximab induction therapy is not available. In our center, 
41 patients were enrolled in the multicenter trial CHIB201 in 1995/96 comparing basiliximab 
vs no induction therapy after renal transplantation. We retrospectively analyzed the outcome 
of these patients after 10 years. The main reason for patient death with functioning graft were 
infectious complications (basiliximab: 3/20, placebo 1/19), 21% of all patients developed 
cancer without an obvious correlation to speciﬁ  c immunosuppression. Death censored 10-year 
graft survival was equivalent in both groups: 65% in the basiliximab and 68% in the placebo 
group with a mean s-creatinine-clearance of 60 and 44 ml/min. In this small study patient and 
graft survival was equivalent 10 years after transplantation comparing basiliximab induction 
therapy and placebo.
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Introduction
Basiliximab (Simulect®) is a chimeric monoclonal antibody directed against the alpha 
chain of the interleukin-2 receptor (IL-2R) and competitively inhibits IL-2 dependent 
T-cell activation in acute allograft rejection.1 Basiliximab induction therapy has 
proven in large clinical trials to be effective to reduce the rate of acute rejections and 
to allow sparing of calcinurin inhibitors (CNI) and steroides in the early postopera-
tive period after renal transplantation (RTx) with similar tolerability to placebo.2–4 
Most studies focus on acute rejection rates and one year allograft survival, but less 
is known about the impact of induction therapy with IL-2R antagonists on long term 
allograft survival.
Since it is known that acute rejections are a risk factor for chronic transplant 
dysfunction,5–7 an effective induction therapy might have a beneﬁ  cial long-term effect 
on renal function.
Other than induction therapies with antithymocyte globulin (ATG) or anti-CD3 
monoclonal antibody (OKT3)8,9 no signiﬁ  cant increase in malignancies or infections 
was related with the application of basiliximab in the ﬁ  rst years after RTx,4,10 but long 
term evaluations are sparse.
In this study we address the question if antibody induction therapy with basiliximab 
compared to no induction therapy leads to better long term renal allograft function 
and/or patient survival after 10 years. We retrospectively analyzed patients enrolled 
in a multicenter phase III trial (CHIB 201)3 at Hanover Medical School, Germany in Biologics: Targets & Therapy 2009:3 52
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1995/1996. Patients were treated either with basiliximab 
or placebo in combination with cyclosporine A (CyA) and 
steroides after ﬁ  rst cadaveric renal transplantation and were 
followed over a 10-year period. The results of this study 
were compared with published long-term data available for 
other IL-2R antagonists.
Methods
Study design and patients demographics
We retrospectively analyzed the outcome of 41 recipients 
of primary cadaveric renal allografts enrolled in the 
CHIB 201 study at Hanover Medical School, Germany in 
1995/1996. The primary objective of the CHIB 201 study 
was to analyze the rate of acute rejections in the ﬁ  rst six 
months after kidney transplantation in combination with 
standard immunosuppressive therapy consisting of CyA 
and corticosteroids.
Twenty one patients received 20 mg of basiliximab on 
days 0 and 4 post-transplantation and 20 patients received 
placebo. Induction therapy was combined with standard 
immunosuppressive therapy consisting of CyA and corti-
costeroids. There were no relevant differences between the 
placebo and the basiliximab group regarding demographic 
data and medical condition at time of transplantation. 
Gender, age, and reason for transplantation are shown in 
Table 1.
Immunosuppression
Initial immunosuppression consists of low doses of CyA and 
corticosteroids with or without basiliximab induction therapy. 
The mean CyA trough levels have been 130–150 ng/ml 
in both groups within the ﬁ  rst three months in our center. 
In case of acute rejection treatment was performed with 
bolus injections of 500 mg methylprednisolone given 
intravenously for three days without a change in baseline 
immunosuppression. If this was without success patients 
received OKT3 in a dose of 5 mg/day for 7–8 days. No routine 
biopsies were performed.
Long term evaluation
Patients were followed for 10 years by using clinical 
examination and laboratory tests done in our outpatient 
facility at least once a year. If visits in our centre were not 
possible records provided by the patients local nephrologists 
were used for long-term follow up.
Follow up was terminated at the time patients returned 
to dialysis or died.
Creatinine clearances were calculated using the 
Cockcroft–Gault formula:11 (140 – age) × (weight/(72 × 
creatinine (μmol/l)/88.4)) for male and multiplied with 0.85 
for female patients.
Statistics
Statistical signiﬁ  cance of differences in renal function was 
calculated using Students t-test (Microsoft Excel, Microsoft 
Corp., Redmond, WA) and patient and graft survival was 
analyzed by Kaplan–Meier estimates using Wilcoxon signed-
rank tests. P  0.05 was given as signiﬁ  cant.
Results
Patient and graft survival after 10 years
As in the multicenter trial3 in the subgroup of patients 
analyzed here acute rejections in the ﬁ  rst six month post-
transplantation were signiﬁ  cant higher in the placebo group 
(55% vs 29%). No steroid resistant rejections occurred in the 
basiliximab group, while in the placebo group ﬁ  ve patients 
were treated with OKT3.
In both groups one patient was lost for follow up within 
the ﬁ  rst year after transplantation and was excluded from 
the long term analysis.
In the basiliximab group three patients (3/20) died with 
functioning graft within 10 years after transplantation resulting 
Table1 Gender, age and reason for transplantation in the placebo and the basiliximab group
Basiliximab group Placebo group
Male/female 10/10 13/6
Age at time of transplantation (years) 46 ± 12 47 ± 14
Reasons for transplantation:
– Glomerulonephritis 4 5
– IgA nephritis 4 1
– Cystic kidney degeneration 2 4
Interstitial nephritis/pyelonephritis 4 4
Others/unknown 6 5Biologics: Targets & Therapy 2009:3 53
10-year results of basiliximab in renal transplantation
in a patient survival of 85%. Reasons for death were: sarcoma 
(three years post-RTx, age 68), Pneumococcus pneumonia 
(four years post-RTx, age 59) and sepsis (Pneumocystis 
carinii pneumonia, seven years post-transplantation in the 
age of 44 years).
Seven patients lost their grafts in the basiliximab group, 
due to the following reasons: two vascular complications 
immediately after transplantation, ﬁ  ve patients returned to 
dialysis due to long term renal failure. Reasons were (biopsy 
conﬁ  rmed): in three patients recurrent renal disease (2 × IgA 
nephropathy, 1 × light chain amyloidosis) ﬁ  ve, six and seven 
years after transplantation and chronic rejection and/or 
CNI-toxicity in two patients after 10 years. 10/20 patients 
(50%) had a functioning graft after 10 years (Figure 1). 
Death-censored graft survival in the basiliximab group was 
65% after 10 years.
In the placebo group, patient survival was 95% after 
10 years; one (1/19) patient died from sepsis three years 
after transplantation with functioning graft with 52 years. 
In the placebo group six graft losses occurred: One due 
to anemic infarction 20 days after transplantation, three 
patients lost their graft due to chronic rejection (5, 6, and 
9 years after RTx) and one patient due to hypertensive dam-
age and CNI toxicity after 6 years. Considering one patient 
dying with functioning graft 12/19 patients (63%) had a 
functioning graft 10 years after transplantation (Figure 1). 
Death-censored graft survival in the placebo group was 
68% after 10 years.
For both groups, 22 of 39 kidneys were functioning 
10 years after transplantation, this is a graft survival of 56% 
for all patients, death-censored 67%.
Renal function after 10 years
In the basiliximab group, 10 patients with a functioning graft 
have S-creatinine values between 93 and 158 μmol/l and a 
mean creatinine-clearance of 60 ml/min. In six patients renal 
function was improved or stable (clearance ± 10 ml/min) 
from year 1 to year 10 after transplantation, in four patients 
renal function was decreasing (Figure 2a).
In the placebo group 12 patients with functioning grafts 
had S-creatinine values between 78 and 332 μmol/l and 
a mean clearance of 44 ml/min. Six grafts displayed an 
improved or stable function (clearance ± 10ml/min compared 
to year one) over ten years and in six patients renal function 
declined (Figure 2b).
Immunosuppression
In the basiliximab group, no OKT3 treatment was needed 
for acute steroid-resistant rejection, while ﬁ  ve patients in the 
placebo group received OKT3.
Ten years after transplantation, 9/10 patients with func-
tioning graft in the basiliximab group were on CyA-based 
immunosuppression, five of them in combination with 
either mycophenolate mofetil (MMF) or azathioprine 
(AZA). One patient takes rapamycine due to the diagnosis 
of melanoma.
In the placebo group 9/12 patients are treated with 
CyA-based immunosuppression, three of them in combination 
with MMF or AZA. Two patients are on tacrolimus-based 
immunosuppression and one patient with kaposi-sarcoma 
takes AZA and steroids only.
Four of ﬁ  ve placebo-patients treated with OKT3 had 
functioning grafts after 10 years.
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Figure 1 Ten-year graft survival in the basiliximab and the placebo group. There was no signiﬁ  cant difference in graft survival between both groups.Biologics: Targets & Therapy 2009:3 54
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Malignancies
In the basiliximab group, six malignancies were reported 
in ﬁ  ve patients: One patient died from sarcoma three years 
post-RTx, a second was nephrectomized due to renal cell 
carcinoma in his own kidney four years post-transplantation, 
a third patient developed spinocellular carcinoma of the upper 
lip after eight years, a forth patient developed a T1 melanoma 
and a basalioma after nine years and a female patient was 
diagnosed with lung and liver metastasis of a carcinoma of 
the vagina after 10 years.
In the placebo group, three malignancies occurred. One 
patient developed kaposi sarcoma 18 months post-transplan-
tation, and is now doing well 10 years post-RTx, a second 
patient developed spinocellular carcinoma of the lower lip 
after ﬁ  ve years, and a third patient suffered from bladder 
carcinoma in the eighth year after transplantation.
In both groups, three nonmelanoma skin cancers and six 
other cancers including melanoma were found in 8/39 (21%) 
patients. Seven of eight patients are alive with functioning 
grafts after 10 years.
Discussion
The IL-2 receptor antagonist (IL-2RA) basiliximab has proven 
to be effective in reducing acute rejection episodes in large 
double blind multi center trials without signiﬁ  cant side effects.2,3 
Due to these promising results, basiliximab is now commonly 
used, but sparse analysis on its long-term effects exist.
A report on the murine IL-2RA BT563 vs placebo after 
renal transplantation shows a comparable 10-year patient and 
graft survival without increase in malignancies12 and a study 
comparing induction therapy with the rat IL-2R antagonist 
Lo-tact-1 and ATG demonstrated no difference in patient and 
graft survival after 10 years, but a tendency to less chronic 
rejection in the Lo-tact group.13
No 10-year follow-up data on basiliximab is available at the 
moment. A ﬁ  ve year analysis by Kyllönen and colleagues com-
pares basiliximab–induction with ATG-induction and standard 
immunosuppression without induction primarily to analyze 
effects on delayed graft function, showing no difference 
between both induction groups for patient and graft survival, 
but a superior ﬁ  ve year graft survival for the basiliximab group 
compared to induction-free immunosuppression.14
Taken together, the results of these studies do not clearly 
demonstrate a long-term beneﬁ  t for IL-2R antagonists com-
pared to other induction therapies or to no induction regarding 
patient or graft survival.
The CHIB 201 study, we used for retrospective analy-
sis, was designed to compare basiliximab induction versus 
no induction therapy in combination with a low dose dual 
basic immunosuppression consisting only of CyA and cor-
ticosteroids. The study demonstrated an excellent reduction 
of acute rejections for all patients3 and the patients included 
in this sub-analysis despite of relatively low CyA levels in 
our centre. The number of patients requiring urbason bolus 
therapy for acute rejection within six months was reduced 
in the basiliximab group and more important no OKT3 or 
other antibody therapy was needed in the basiliximab group 
for treatment of steroid resistant rejection.
With regard to the common suggestion of acute rejections 
as a risk factor for chronic graft dysfunction, our hope was 
to improve long term allograft survival in patients free of 
acute rejections, but as in the studies mentioned above, we 
found comparable patient survival of 85%/95% and death-
censored graft survival of 65%/68% in the basiliximab and 
placebo group. Neither patient nor graft survival was sig-
niﬁ  cantly different. This result may underline the fact that 
acute rejections are only one risk factor in the multifactorial 
process of chronic graft loss.
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Figure 2 Changes in creatinine-clearance from year one to year ten after transplantation in patients with functioning graft at the end of the observation period. A) basiliximab 
group, B) placebo group.Biologics: Targets & Therapy 2009:3 55
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By taking a closer look at each patient, it is remarkable 
that in patients of the placebo group diagnosis of early acute 
rejection seems not to be necessarily correlated with worse 
long term graft function. All four patients after successful 
OKT3 treatment due to steroid-resistant rejection have 
functioning grafts after 10 years.
Kidney function in patients receiving basiliximab tended 
to be better after 10 years, but in both groups ﬁ  ve chronic 
grafts losses occurred. They comprise of recurrence of pri-
mary disease as well as chronic rejection and/or CNI toxicity 
in both groups, again showing the multifactorial ethiology 
of chronic allograft dysfunction.
Other than in registry data, main reasons for patients’ 
death in this study were not cardiovascular events, but 
infectious complications years after transplantation in both 
groups.
Malignancies become a challenge after transplantation 
since time of immunosuppression increases due to improved 
patient survival, as well as rising numbers of retransplanted 
and young patients. The incidence of most types of cancers is 
increased after transplantation and the number of malignan-
cies found in our study is in accordance with reported rats 
of non melanoma skin and other cancers.15–17 An associa-
tion of malignancies and immunosuppression in general is 
clearly proven, but a correlation with deﬁ  ned drugs is more 
difﬁ  cult. In this study the sarcoma was found in a patient on 
tacrolimus based triple immunosuppression, while the other 
patients with malignomas in the basiliximab group were on 
dual therapy. One patient after OKT3 treatment in the placebo 
group developed cancer (urothel carcinoma). The patient 
diagnosed with a kaposi sarcoma was a placebo patient, 
who received an acute rejection treatment with steroids and 
was switched to tacrolimus based immunosuppression for 
the same reason within the ﬁ  rst month post-RTx. After 10 
years of immunosuppression, at least 1/3 of patients suf-
fered from cancer including skin cancers, but luckily only 
one patient died.
In summary we achieved a comparable patient and graft 
survival 10 years after renal transplantation with and without 
basiliximab induction therapy. While graft function in the 
basiliximab group tended to be better, the number of graft 
losses due to chronic damage including recurrence of primary 
disease was equal in both groups. Our results are consistent 
with reports available for other IL-2R antagonists and are not 
able to prove an improved long term graft or patient survival 
after basiliximab induction therapy. Since these are the only 
10-year results available comparing basiliximab induction 
therapy with placebo and the number of patients analyzed 
is small, the conclusions from this study must be drawn 
carefully. Although basiliximab induction therapy is com-
monly used today, it seems worth to rethink the indication 
of induction therapies and to focus on further investigation 
on the effects of different immunosuppression on long term 
allograft survival.
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